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Pregnancy, labor, and delivery are accompanied by physiological changes that 
impact on the use of the drugs to which they are exposed. The anesthesiologist 
needs to understand the principal differences in management of this particular 
population. The study of the main pharmacokinetic changes associated with preg-
nancy is relevant for the proper management of drugs to avoid adverse effects. The 
objective of this chapter is to review the physiological changes that impact on the 
pharmacokinetics of the pregnant woman with a focus on local anesthetics of  
the amide type, specifically bupivacaine, and the main studies that have led to a 
deeper understanding.
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1. Introduction
Pregnancy and labor are accompanied by important physiological and anatomi-
cal changes. There is a modification in the metabolism of drugs and changes in their 
pharmacokinetics as well as their interaction with organs and systems. Anesthesia 
in the obstetric patient is influenced by physiological changes, concomitant dis-
eases, and preferences for a specific drug. Local anesthetics are a special topic due 
to the frequent use of them during labor, the performance of cesarean section, or 
another non-obstetric procedure in the pregnant patient. It is necessary to know 
the pharmacokinetics of the local anesthetic most frequently used in our practice, 
bupivacaine, plain or hyperbaric, or one of its enantiomers. The objective of this 
review is to know the main studies that have evaluated pharmacokinetics and their 
interaction with systems and organs in the mother and placental passage.
2. Cardiovascular changes of pregnancy
During pregnancy many hemodynamic and hormonal changes occur like cardio-
vascular adaptations such as increased heart rate, plasmatic volume, cardiac output 
and sympathetic tone, or a reduction in peripheral resistances. The heart moves to 
the left and up during pregnancy, since the diaphragm progressively rises through 
the gravid uterus. These changes may be more important in post-term periods that 
are defined as pregnancies greater than 294 days (≥42 weeks of gestation periods) 
[1]. The increase in cardiac output and blood volume may increase the distribution 
of some drugs; the water-soluble ones will increase in their absorption as well as the 
liposoluble by the augmentation of the maternal fat, and there is an increase of the 
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glomerular filtration and the renal sanguineous irrigation, which will produce an 
increase in the clearance of the drug [2].
The blood volume increases by 30–50%, and this rise begins in the first trimester 
and continues rising until week 30 of gestation and returns to its normal volume 
after pregnancy. A phenomenon is a dilutional anemia since the proportion of 
plasma volumes in relation to blood volume increases proportionally greater than 
red cells, and the hemoglobin concentrations will vary between 11 and 12 g/100 mL 
at the end of pregnancy. The increase in plasma volume is related to the size of the 
fetus; one theory is that the adrenal glands of the fetus can initiate an increase in 
blood volume by providing dehydroepiandrosterone (precursor of estrogen) to the 
placenta, stimulating the liver to produce angiotensin, which increases aldosterone 
production and fluid retention [3].
Increased blood volume and increased cardiac output may respond to an initial 
vasodilation caused by a vasodilating substance that may be prostacyclin or the 
endothelial-derived relaxing factor. This increase in blood volume is necessary 
to meet the needs of the fetus and compensate for the loss of maternal blood at 
delivery; the mother can lose up to 20% of their blood volume without a significant 
change in his hematocrit [3]. Cardiac output increases to 30–50% during preg-
nancy, peaks at weeks 28–32, and then decreases a little during the last weeks. The 
values increase to 4.5–6.5 L/min and decrease as the term of pregnancy approaches 
but are considerably lower in the lateral position than in the supine position. The 
supine position during labor is associated with an 8% incidence of hypotension, and 
15–20% of patients will have aortoiliac and vena cava compression. The reduced 
cardiac output lowers uterine blood flow, and this adversely affects the fetus. The 
cardiac return is diverted from the vena cava through the vertebral and azygos 
systems to the superior vena cava, and this enlarges the epidural veins and provides 
an explanation for the reduced amount of local anesthetic needed for spinal or 
epidural analgesia in pregnancy, and there is an increase in sympathetic activity that 
results in vasoconstriction that reduced the degree of hypotension observed [4].
Uterine blood flow increases to 200 mL/min by week 28 and 500 mL/min by 
the end of pregnancy, the uterine musculature receives approximately 20% of the 
total uterine blood flow, while the area of the placenta receives 80% by what to the 
placenta, that is to say, 400 mL of blood per minute or approximately 80 mL of 
blood per 100 g of tissue per minute [4].
3. Pharmacokinetics of bupivacaine and main studies
Bupivacaine is a local anesthetic amide type, synthesized in 1957 by Ekenstam 
in Switzerland, and has a mechanism of action through the obstruction of sodium 
channels to the nerve membrane, preventing the generation of an action potential. 
It is used for intraoperative local anesthesia, postoperative analgesia, and chronic 
pain treatment. It is widely used in pregnant patients and provides excellent sensory 
anesthesia with reported concentrations at 0.5% [5].
The effectiveness of bupivacaine was evaluated by the toxicity, the latency,  
and the degree of motor block, the sympathetic block, and the sensory block, 
as well as the elimination time. The absorption and distribution are influenced 
by the vascularity of the injection site, the mode of injection, and the degree of 
ionization of the drug. After IV administration, its half-life is 45 min correspond-
ing to redistribution and 2.5 h due to elimination. It is metabolized by the liver by 
N-dealkylation and glucuronide conjugation. Elimination is urinary. Although some 
metabolites are eliminated via the pulmonary and bile fluid, the portion bound to 
proteins is the active part, and the unbound is responsible for the toxic effects [5].
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The pharmacokinetics in the mother-fetus binomial changes, the fetus and the 
placenta function as deposits, the placenta has the capacity to metabolize drugs, and 
it is possible to modulate the elimination of the drug by producing metabolites and 
retaining large quantities for its release back to the fetus [6].
The apparent volume of distribution increases during pregnancy with the 
increase in plasma volume, approximately 40–50% from the beginning of preg-
nancy to a maximum of 32 weeks. During the placental growth phase, the periph-
eral hairy surface increases from 3.7 m2 in week 25 to 11 m2 during the last month of 
gestation, and the fetal-mother exchange surface decreases from 92 to 767 m2 due to 
a decrease in density of the microvilli [6].
Since the drugs that cross the placenta reach the fetus via the umbilical venous 
blood and 50% of it enters the liver circulation and the rest goes through the venous 
duct, then half of the transported drug is susceptible to hepatic metabolism and the 
other half enters the fetal circulation directly. The distribution of a drug in the fetus 
is regulated by variations in pH and protein binding [6].
The drugs once inside the organism move between the compartments, and to 
analyze it the changes in the concentration of the drug in a compartment as a func-
tion of time are studied, according to the following formula [7]:
  dC ___
dt
 = − kCn (1)
where dC/dt equals the change in concentration in relation to time and −kCn 
refers to the decrease in the concentration of a drug which is an exponential type 
function [7].
When the rate of change is independent of the concentration of the drug, it 
is called a zero-order process, and when the process and the rate of change are 
proportional to the concentration of the drug, it is called a first-order process, the 
mother-fetus, which behaves like a model of two compartments with bidirectional 
distribution [7].
Bupivacaine has an asymmetric carbon atom and can take the form of two 
enantiomers (R + dextrobupivacaine and S-levobupivacaine), form different three-
dimensional relationships in the asymmetric medium of receptors and enzymes, 
and result in differences in toxicity, distribution, cardiotoxicity, and neurotoxicity 
[8]. Levobupivacaine is soluble in water with a molecular weight of 325, a partition 
coefficient of 1624, and a pKa of 8.09. Both the partition coefficient and the pKa 
are very similar to those of bupivacaine. Its pH is 4.0–6.5. Its maximum plasma 
concentration reaches 30 min, and its volume of distribution is 67 L [8]. Liposomal 
bupivacaine is composed of multivesicular liposomes with 10–30 micrometers in 
diameter and has a duration of analgesia of up to 72 h [9].
Bupivacaine has a pKa of 8.1, ionized fraction of 15% at a pH of 7.4, fat/buffer 
coefficient of 115, protein binding 95%, molecular weight of 288 Daltons, and 
an effective anesthetic concentration in the rat sciatic nerve of 0.25. The main 
determinant of adverse systemic effects is the free fraction, which is not bound 
to proteins [10].
4. Studies of bupivacaine in QT interval
Spinal anesthesia involves changes in the mother’s hemodynamic, including 
decreased venous return, decreased systemic vascular resistance, and a compensa-
tory increase in cardiac output. These changes increase the risk of intraoperative 
arrhythmias in patients [1].
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Local anesthetics routinely used include bupivacaine and its enantiomer levobu-
pivacaine, the latter having a clinical profile close to bupivacaine, but it is less toxic 
to both the nervous system and the cardiovascular system, which makes it useful in 
obstetric anesthesia, where large volumes of local anesthetics may be required. It has 
been reported that bupivacaine and levobupivacaine cause a concentration-dependent 
inhibition of the amplitude of gravid myometrial contractions in rats [11].
Local anesthetics are amphiphilic and can enter a variety of cellular compart-
ments and potentially interact with many different cell membranes, organelles 
(including the inhibition of mitochondrial adenosine production), and a variety of 
membrane junctions and charged cytosol molecules. Other mechanisms, which can 
contribute to myometrial inhibition, include the blocking of ionotropic signaling 
pathways (sodium, potassium, or calcium) and interference with protein modula-
tion of calcium and potassium channels [11].
The practice of using low concentrations (0.125–0.25%) makes it less likely that 
the inhibitory concentrations in the plasma reach the clinical practice [11]. The 
toxic effect of local anesthetics on myocardial contractility and cardiac conduction 
is due to the alteration of the calcium channel [12]. In a study by Mahmut et al., 
40 healthy pregnant patients were included; they evaluated QT interval, which 
increased significantly in the post-term group, which makes them susceptible to the 
development of arrhythmias; and they concluded that care must be taken during 
the induction of spinal anesthesia in term pregnancies as well as cardiovascular 
monitoring should be prolonged in this type of patients [20].
The Dogan et al. study used 12 mg of 0.5% hyperbaric bupivacaine or 0.5% of 
levobupivacaine for the spinal levobupivacaine group and calculated the QTc with 
the Bazzett formula and the QT dispersion (difference between the maximum and 
minimum QTc). They studied 60 patients. The mean maximum QTc was longer in 
levobupivacaine, and the minimum mean QTc was also longer. In the bupivacaine 
group, the maximum QTc was longer than levobupivacaine [17].
5. Pharmacokinetic studies in rats
It is known that the placenta does not limit the fetal transfer of local anesthetics 
administered to the mother; using a human placental model in rats, it is suggested 
that bupivacaine accumulates in the placenta [13]. The study of Morishima et al., 
a study in the University of Columbia with a model of rats, administered 1 mg/kg 
of bupivacaine followed by an infusion of 0.33 mg/kg/min, over a total period of 
15 min. The maximum dose of bupivacaine was 1200–1400 ng/mL, which is similar 
to the concentration of plasma bupivacaine in pregnant women under cesarean 
section with epidural anesthesia [1].
The pharmacokinetic analysis of bupivacaine was assumed as an open two-
compartment model. A transient reduction in heart rate occurred during the 
infusion of bupivacaine [1].
5.1 Pharmacokinetic parameters
The mean peak concentration of bupivacaine in maternal plasma was 
3123 ± 370 ng/mL, the concentration decreased to 26 ± 12 ng/mL at 180 min, 
and after 240 min, it became undetectable. In plasma 4′-hydroxybupivacaine 
and 2,6-pipecoloxylidine were not detected. The half-life of distribution was 
37.7 ± 2.4 min, the volume of distribution in stable state 3.86 ± 0.29 l/kg, and the 
total clearance 93.3 ± 8.6 mL/min−1.kg−1; other parameters were K12 0.462 ± 0.066; 
K21 0.081 ± 0.008 and K10 0.166 ± 0.021. In fetal plasma, a bupivacaine peak of 
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320 ± 38 ng/mL was detected rapidly, and the drug became undetectable at 4 h. A 
bupivacaine concentration of 4817 ± 976 ng/g in the amnion at the end of the infu-
sion was the highest sample of those obtained at any time [1].
While the dose of bupivacaine decreases, 3-hydroxybupivacaine remains virtually 
constant in the amnion and myometrium, and the 3-hydroxybupivacaine also kept 
increasing. Despite a high concentration of 3-hydroxybupivacaine in these tissues, the 
amniotic fluid concentration was not as high as expected. The 4-hydroxybupivacaine 
and the 2.6 pipecoloxylidide were only detected in traces in samples obtained in 2 h. 
The largest metabolite detected in rats was 3-hydroxybupivacaine [1].
In the fetus, the 3-hydroxybupivacaine remains detectable in the liver up to 4 h, 
while it virtually disappears from other tissues, because most of the umbilical venous 
blood perfused in fetal liver, and bupivacaine transmitted to the fetus, can directly 
enter the fetal liver; this may suggest that the fetal liver is capable of metabolizing 
bupivacaine. However, because polar metabolites do not cross the placental mem-
brane bidirectionally, 3-hydroxybupivacaine probably accumulates in the fetus [1].
6. Studies about bupivacaine in multimodal analgesia
6.1 Blockage of the transverse abdominal muscle
In the study by Eslamian et al., a randomized, double-blind, placebo-controlled 
study of 50 pregnant women under elective cesarean section, transverse abdominis 
plane (TAP) block was used. The preparation was performed with 40 mL of 0.25% 
hyperbaric bupivacaine plus 2 mL of normal saline for the placebo group of 400 mL 
of 0.25% hyperbaric bupivacaine plus 2 mL of sufentanil for the study group. The 
block was guided with ultrasound; the patients who received 40 mL of hyperbaric 
bupivacaine 0.25% plus 10 μg of sufentanil consumed less morphine during 24 h after 
surgery compared to the control group (p = 0.002); the mean difference in morphine 
consumption was 15.6 mg in the first 24 h of the postoperative period. There were no 
differences in the EVA scale between one group and another with>0.05 [13].
In the Trabelsi et al. study, a group of 17 pregnant patients were administered 
with spinal anesthesia with hyperbaric bupivacaine with 5 μg of sufentanil, and 
abdominal ultrasound-guided TAP block was placed with 20 mL 0.25% bupivacaine 
bilaterally. They found an accumulated average of bupivacaine of 1.4 ± 0.2 mg/kg 
(range of 1.05–1.79 mg/kg); the CMAX was 802.36 ng/mL (231.8–3504.5 ng/mL) and 
was reached at 30 min (TMAX). The mean area under the curve (AUC) (0–24 h) was 
4505.4 ng/mL, and the elimination half-life was 8.75 h for bupivacaine, demonstrat-
ing that bilateral blockade increases the total concentration of bupivacaine in the 
plasma after administering spinal anesthesia with bupivacaine. Plasma concentra-
tions occurred at 30 min after injection, all peak concentrations were reached 
between 10 and 90 min and a second delayed peak of 90 min [10].
In the Lacassie study, in 12 pregnant women and 11 healthy volunteers, the 
transverse muscle was blocked with levobupivacaine 0.25%, 20 mL with epineph-
rine 5 μg/ml−1, venous concentrations were 2.62 mg/L−1, below the level toxic, the 
volume of distribution of levobupivacaine was 172 L (70 kg) (IC 95% 137–207) 
higher than in healthy volunteers [15].
6.2 Use of patient-controlled analgesia (PCA pumps) in different combinations
The Stourac study worked with pregnant women under epidural analgesia; they 
used 12.5 mg of bupivacaine and 5 μg of sufentanil in 10 mL of normal saline, and 
boluses of half the dose every 60–90 min were administered. Another group using 
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PCA pumps with remifentanil connecting a 50 mL syringe with remifentanil at a 
concentration of 20 μg/mL studied a total of 24 patients, and there was no signifi-
cant difference between the groups. The level of satisfaction of the patients was 
88% with epidural analgesia and 85% with PCA pump. Among the complications, 
only one had hypotension, with remifentanil, and experienced drowsiness and 
dizziness as well as temporary anxiolysis [8].
In the Chen et al. study, they determined the lowest effective concentration of 
levobupivacaine and levobupivacaine with fentanyl, and one group received 1.2 mg/mL 
of levobupivacaine and 2 μg/mL of fentanyl. They determined that the concentrations 
of 0.6 mg/mL of levobupivacaine plus 2 μg/mL of fentanyl and 1 mg/mL of levobupiva-
caine were the lowest concentrations of the drugs required for effective analgesia, and 
they analyzed a total of 83 pregnant women and showed that levobupivacaine alone 
produces a comparable analgesia with levobupivacaine with narcotic; in addition, those 
who received narcotics had more adverse effects [16].
6.3 Studies in the capacity of blocking muscle fibers
In the Fanning et al. study, pregnant patients received spinal anesthesia with 
10–12 mg at 0.5% hyperbaric bupivacaine with 20–25 μg of intrathecal fentanyl and 
100–150 μg of intrathecal morphine. After the placental extraction, a small segment 
of the myometrium was removed from the incisional surface of the lower uterine 
segment. Each sample was dissected in four longitudinal muscles. The muscle 
was exposed to bupivacaine or levobupivacaine and chemical contractions were 
induced. Eight muscle samples were included. Bupivacaine and levobupivacaine 
caused a concentration-dependent decrease in the amplitude of the contractions 
reaching a statistical significance of p = 0.002 for bupivacaine and p = 0.001 for 
levobupivacaine compared to the control period before the administration of any 
drug [14]. There was no significant difference between bupivacaine and levobu-
pivacaine in its effects on contraction of the myometrium, in the amplitude of the 
contractions, and in the interval between contractions for bupivacaine and levobu-
pivacaine; there was no difference between the EC50 (effective concentration 50)  
and the effect of both drugs in contractility which was reversible. No increase in 
contractile amplitude was observed. The maximum concentrations in plasma were 
1053 μg/mL (3.24 × 10–6 m) for bupivacaine and 1017 μg/mL (3.13 × 10–6 m) for 
levobupivacaine. They concluded that bupivacaine and its enantiomer levobupiva-
caine cause a similar decrease in concentration-dependent contractions. The con-
centrations required for their inhibitory effect on the amplitude of the contractions 
were much higher (33 times) than the clinically relevant plasma concentrations of 
these drugs after epidural administration and are unlikely to be significant in the 
low epidural dose scenario to analgesia in labor periods [14].
The combination with clonidine, a partial agonist of alpha 2 adrenergic recep-
tors, interacts with the local anesthetic in the neural axis. The analgesic effect 
is due to its action in spinal and supraspinal α-adrenergic receptors, including 
the activation of postsynaptic α-2 receptors, since the noradrenergic descending 
pathways of cholinergic neurons and the release of nitric oxide and substances such 
as enkephalin reduce the absorption of local anesthetics by a vasoconstrictor effect, 
improving quality and increasing the duration of anesthetic blockade. It is recom-
mended at doses of 1 μg/kg combined with bupivacaine [12]. In a Brazilian study, 
66 pregnant patients were divided into two groups: a group with 8 mg of bupiva-
caine +75 μg of clonidine and 100 μg of morphine +0.9% saline and another group 
with 10 mg of bupivacaine +75 μg of clonidine +100 μg of morphine + saline 0.9%; 
the total volume administered was 4 ml in both groups, and there was no difference 
in hemodynamic parameters, adverse effects, and level of consciousness, only the 
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regression time of the motor block, in group 1, of 198.48 ± 47.63 min, and in group 2 
of 232.84 ± 63.66 min; p = 0.00073. They concluded that morphine and clonidine at 
low doses produce adequate postoperative analgesia in pregnant patients [12].
In the study Zhan et al., 70 pregnant or obstetric patients were studied; 0.5% 
spinal isobaric bupivacaine was 4 mg; the ED50 of intrathecal bupivacaine for 
motor block was 3.96 mg (IC 95% 3.83–4.98) for pregnant women versus 4.51 mg 
(95% CI 4.27–4.76) for nonpregnant women. The potency of bupivacaine for 
motor block in pregnant versus non-pregnant women was 1.14 times higher  
(95% CI 1.05–1.24). This is because the supine position can increase the dis-
semination of the injected drugs due to the increase in intra-abdominal pressure, 
in addition to the increase in blood flow in the vasculature in the epidural veins, 
which distends and compresses the intraspinal space decreasing the volume of the 
spinal fluid cerebral [18].
7. Bupivacaine and placental transfer to fetus
The analysis of the placental intervillous space shows to be an appropriate place 
of investigation because this space is initially filled with blood coming from the 
maternal spiral arteries that interchange with the fetal venous blood, when the 
blood of the mother flows toward the branched villi. Although it is an important 
interchange interface, the intervillous space has been studied as the transport of 
substances between the mother, the placenta, and the fetus; obtaining blood from 
this compartment has provided a unique opportunity to study the maternal-fetal 
physiological relationship in a more physiological way [19]. The importance of this 
is that the reduced ability of the fetus to eliminate drugs can cause prolonged effects 
on the fetus, since half of the fetal circulation reaches the umbilical vein and directly 
reaches the fetal heart and brain by passing to the fetus. Liver immaturity contributes 
to the  presentation of adverse effects, the fetus eliminates the drug by diffusion into 
the maternal compartment, although the majority of the metabolites are more polar 
and it is unlikely that the placental membrane crosses the placental membrane back 
to the compartment maternal, possibly resulting in the accumulation of metabolites 
in various fetal tissues [19].
In the study by Barros et al., a Brazilian study, the concentrations of bupivacaine 
and lidocaine as well as its metabolite (MEGX) and its placental transfer were 
analyzed in 10 healthy pregnant patients, under elective cesarean and epidural 
anesthesia. The administration of the medication was epidural of 0.1 mg of fentanyl 
citrate, 112.5 mg of 0.5% bupivacaine with 2:200000 epinephrine, and 200 mg 
of lidocaine 2% without vasoconstrictor injected into the epidural space [11]. The 
concentrations of bupivacaine enantiomers were high in the maternal plasma and 
placental intervillous space than in the umbilical vein and the umbilical artery. 
The concentrations of S-bupivacaine in the maternal plasma were higher than the 
R-bupivacaine concentrations, and the values  were 195.2 and 186.0 ng/mL. There 
were no significant differences (P < 0.05) between their concentrations in umbilical 
fetal vessels [11]. The placental transfer was 33% for R-bupivacaine and 31% for the 
S-bupivacaine. The concentrations of the enantiomer S-bupivacaine were 3.5 and 
3.82 times higher in the placental intervillous space than that of the umbilical vein 
and the umbilical artery, respectively [11].
The R-bupivacaine concentrations were 2.9 times higher in the placental inter-
villous space than the fetal umbilical vein concentrations and 3.16 times higher than 
the concentrations in the fetal umbilical artery. There were no cardiocirculatory 
changes, neonatal repercussions in the APGAR, or respiratory depression. There 
was no significant difference in the ratio of enantiomer concentrations between the 
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different compartments, maternal or fetal. This study showed that the intervillous 
space acts as a drug reservoir [11].
8. Conclusion
In conclusion, local anesthetics, including bupivacaine, are among the drugs 
most commonly used in clinical practice for the management of pregnant patients 
for obstetric or non-obstetric procedures. It is essential to know the pharmacokinet-
ics of the drug in order to understand the concentrations of the drugs which we 
can obtain adequate analgesic and anesthetic effects, trying to diminish the toxic 
effects.
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